Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners studied

08-11-2006

According to recent research published in the journal Environmental Health Perspectives, "Uranium miners are chronically exposed to low levels of radon and its progeny. We investigated whether radon exposure is associated with increased incidence of leukemia, lymphoma, or multiple myeloma in this population."

"We conducted a retrospective case-cohort study in 23,043 uranium miners and identified a total of 177 incident cases of leukemia, lymphoma, and myeloma," explained V. Rericha and colleagues, Charles University. "Detailed information on occupational radon exposure was obtained for the cases and a randomly selected subcohort of 2,393 subjects. We used the proportional hazards model with power relative risk (RR) function to estimate and test the effects of cumulative radon exposures on incidence rates. Incidence of all leukemia combined and chronic lymphocytic leukemia (CLL) alone was positively associated with cumulative radon exposure.

"The RR comparing high radon exposure [110 working level months (WLM); 80th percentile] to low radon exposure (3 WLM; 20th percentile) was 1.75 [95% confidence interval (0), 1.10-2.78; p=.014] for all leukemia combined and 1.98 (95% CI, 1.10-3.59; p=.016) for CLL. Myeloid leukemia and Hodgkin lymphoma were also associated with radon, but RRs were not statistically significant."

The researchers concluded, "There was no apparent association of radon with either non-Hodgkin lymphoma or multiple myeloma. Exposure to radon and its progeny was associated with an increased risk of developing leukemia in underground uranium miners. CLL, not previously believed to be radiogenic, was linked to radon exposure."

Rericha and colleagues published their study in Environmental Health Perspectives (Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners: A case-cohort study. Environ Health Perspect, 2006;114(6):818-822).

For additional information, contact M. Kulich, Charles University, Dept. of Probabil & Statistics, Faculty Math & Physics, Sokolovska 83, CZ-18675 Prague 8, Czech Republic.

The publisher's contact information for the journal Environmental Health Perspectives is: Us Dept. Health Human Sciences Public Health Science, National Institute Health, National Institute Environmental Health Sciences, PO Box 12233, Research Triangle Pk, NC 27709-2233, USA.

Keywords: Prague, Czech Republic, Chronic Lymphocytic Leukemia, Environmental Health, Ionizing Radiation, Leukemogenesis, Lymphoma, Multiple Myeloma, Myeloid Leukemia, Occupational Exposure, Oncology, Radon, Czech Uranium Miners.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Diseases: Non-Hodgkin Lymphoma (NHL), Multiple Myeloma, Hodgkin Lymphoma, Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Related Resources: Institute for Myeloma & Bone Cancer Research (IMBCR), Multiple Myeloma Research Foundation, Leukemia Research Foundation
Related Glossary Terms: NHL, Hodgkin Lymphoma, CML, CLL, AML, ALL
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Cancer drug shows promise against graft vs. host disease
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Acute Myeloid Leukemia (AML)
Genome Sequencer FLX System plus NimbleGen Sequence Capture Arrays Help Unravel the Cryptic Genetic Changes in Hematological Malignancies
Early findings show promise as AS1411 AML study proceeds to higher-dose stage
Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Radiation Therapy for Prostate Cancer Increases Incidence of AML
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
New lymphoma therapies targets diverse and difficult cancer
Chronic Myeloid Leukemia (CML)
Activation of LYN kinase is associated with imatinib-resistance in CML patients
CHEMGENEX'S OMACETAXINE DEMONSTRATES ACTIVITY IN CML PATIENTS WHO HAVE FAILED THERAPY WITH MULTIPLE TYROSINE KINASE INHIBITORS
Best and brightest leukemia researchers receive $1-million from Cole Foundation
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Combination of two novel anti-cancer agents may help fight CML resistant to current therapy
Hodgkin Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Cancer drug shows promise against graft vs. host disease
Hodgkin's lymphoma survivors show higher risk of second cancers
Multiple Myeloma
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure?
Thalidomide Plus Dexamethasone: Improved Primary Myeloma Therapy
Bone Pain Can Be A Sign Of Myeloma - Patients And Doctors Join Forces To Raise Awareness Of Early Myeloma Diagnosis
Lenalidomide raises clot risk in multiple myeloma patients
Myelodysplastic Syndrome (MDS)
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
Non-Hodgkin Lymphoma (NHL)
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Ofatumumab Promising in Refractory Follicular Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer